Placeholder Banner

Importation Scheme Will Jeopardize Patient Health, Do Little to Lower Drug Costs

“Patients deserve access to the medicines they need with out-of-pocket costs they can afford. Under no circumstance should we risk patient safety to achieve this goal, yet that’s exactly what this dangerous importation scheme will do."

December 18, 2019
Media Contact
Author-Profile-Andrew-Segerman

Washington, DC (December 18, 2019) – Following the release of the Trump administration’s drug importation proposal, BIO’s President and CEO Jim Greenwood issued the following statement:

“Patients deserve access to the medicines they need with out-of-pocket costs they can afford. Under no circumstance should we risk patient safety to achieve this goal, yet that’s exactly what this dangerous importation scheme will do. The idea that this plan will result in savings for patients at the pharmacy counter is a talking point that’s been debunked by nonpartisan budget experts and past FDA commissioners who served under both Republican and Democratic administrations.

“Following the recent vote on Speaker Pelosi’s extreme drug pricing plan, today’s announcement is the latest empty gesture from our elected lawmakers who want us to believe they’re serious about lowering patients’ prescription drug costs. It’s time Congress and the administration delivered a holistic solution that protects the health and well-being of patients and ensures medicines are affordable.”

Learn more:

 

###

Discover More
The next farm bill offers an opportunity to examine innovation’s influence on the resiliency of our economy in the face of global challenges, BIO wrote in a statement for the record to the Senate Agriculture Committee's Nov. 15 hearing on energy and…
The Biotechnology Innovation Organization (BIO) is pleased to announce that Beth Ellikidis has joined BIO as Vice President, Agriculture and Environment. In her role, Beth will lead the policy and market access strategies for BIO’s Agriculture and…
Awards Recognize Innovators in Agricultural, Environmental and Industrial Biotechnology   The Biotechnology Innovation Organization today announced Dr. Annie Tsong, chief strategy & product officer at Amyris, as the winner of this year’s…